BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, February 16, 2026
Home » Authors » Mark McCarty

Articles by Mark McCarty

Washington roundup: Neiman Institute offers rubric for evaluating repeat imaging

Feb. 20, 2013
By Mark McCarty

Washington roundup: PTO eases prior disclosure mandate in first-to-file rule

Feb. 19, 2013
By Mark McCarty

Congress and the doc fix: Is 2013 the year?

Feb. 18, 2013
By Mark McCarty
A clumsy attempt to address the Medicare Part B physician fee problem has nagged at Washington for a decade, but it appears Congress is ready to put a doc fix in play. Whether it’ll happen depends on politics and, as a skeptic might argue, some accounting sleight-of-hand, but it appears this is a now-or-never moment. As has been widely noted, the Congressional Budget Office recently released a report proposing a lower figure for the budgetary effects of a repeal of the sustainable growth rate (SGR) mechanism than has been calculated for some time. Instead of the average figure of $30...
Read More

Washington roundup: Hackbarth: delete SGR soon, bolster push on primary care

Feb. 15, 2013
By Mark McCarty

Washington roundup: Bacterin hit by FDA warning letters for bone putty, drains

Feb. 14, 2013
By Mark McCarty

Three really bad ideas

Feb. 13, 2013
By Mark McCarty
It has been said there are shortages in this world, but there has never been a shortage of bad ideas. In fact, the opposite seems to be true. Here are three really crummy ideas we should all hope end up thoroughly debunked. FDA does comparative effectiveness research We’ve tackled this idea before, but unlike fine red wine, this one isn’t improving with age. The Institute of Medicine released a report recently stating that FDA should “have a more rigorous approval process for new technologies,” arguing that...
Read More

Washington roundup: Analyst; local carrier CED here to stay, not often used

Feb. 13, 2013
By Mark McCarty

Washington roundup: Tavenner tapped again for administrator post at CMS

Feb. 12, 2013
By Mark McCarty

Washington roundup: Richner: bundled payment will boost price pressures on industry

Feb. 11, 2013
By Mark McCarty

Washington roundup: Roe; IPAB 'SGR on steroids,' expects repeal to win in House

Feb. 8, 2013
By Mark McCarty
Previous 1 2 … 411 412 413 414 415 416 417 418 419 … 579 580 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing